MX2023008263A - 4-cloro-n[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benz amida para uso en medicina. - Google Patents
4-cloro-n[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benz amida para uso en medicina.Info
- Publication number
- MX2023008263A MX2023008263A MX2023008263A MX2023008263A MX2023008263A MX 2023008263 A MX2023008263 A MX 2023008263A MX 2023008263 A MX2023008263 A MX 2023008263A MX 2023008263 A MX2023008263 A MX 2023008263A MX 2023008263 A MX2023008263 A MX 2023008263A
- Authority
- MX
- Mexico
- Prior art keywords
- thiadiazol
- benzamide
- chlorophenyl
- oxo
- chloro
- Prior art date
Links
- WEDWLYRQKUTOAX-UHFFFAOYSA-N 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 WEDWLYRQKUTOAX-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 abstract 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2100352.0A GB202100352D0 (en) | 2021-01-12 | 2021-01-12 | New methods |
| PCT/GB2022/050054 WO2022153042A1 (en) | 2021-01-12 | 2022-01-11 | 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008263A true MX2023008263A (es) | 2023-09-12 |
Family
ID=74667674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008263A MX2023008263A (es) | 2021-01-12 | 2022-01-11 | 4-cloro-n[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benz amida para uso en medicina. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240082222A1 (https=) |
| EP (1) | EP4277625A1 (https=) |
| JP (1) | JP2024505143A (https=) |
| KR (1) | KR20230159375A (https=) |
| CN (1) | CN117320716A (https=) |
| AU (1) | AU2022208237A1 (https=) |
| BR (1) | BR112023013828A2 (https=) |
| CA (1) | CA3208099A1 (https=) |
| GB (1) | GB202100352D0 (https=) |
| IL (1) | IL304392A (https=) |
| MX (1) | MX2023008263A (https=) |
| WO (1) | WO2022153042A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| WO2025027205A1 (en) * | 2023-08-03 | 2025-02-06 | Betagenon Ab | Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide |
| WO2025252672A1 (en) * | 2024-06-03 | 2025-12-11 | Betagenon Ab | Use of tryptophan and metabolites thereof as biomarkers for treatment methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1625848A1 (en) * | 2004-08-10 | 2006-02-15 | Taro Pharmaceuticals North America, Inc. | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid |
| JP5982281B2 (ja) * | 2009-07-08 | 2016-08-31 | バルティック バイオ アーベー | 医薬として有用な化合物 |
| AU2011281381B2 (en) * | 2010-07-21 | 2015-07-16 | Novartis Ag | Salt and solvates of a tetrahydroisoquinoline derivative |
| KR20190009428A (ko) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물 |
| AU2018448511B2 (en) * | 2018-11-05 | 2025-07-03 | Betagenon Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
| US11691954B2 (en) * | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
-
2021
- 2021-01-12 GB GBGB2100352.0A patent/GB202100352D0/en not_active Ceased
-
2022
- 2022-01-11 JP JP2023541948A patent/JP2024505143A/ja active Pending
- 2022-01-11 EP EP22701013.9A patent/EP4277625A1/en active Pending
- 2022-01-11 US US18/271,627 patent/US20240082222A1/en active Pending
- 2022-01-11 MX MX2023008263A patent/MX2023008263A/es unknown
- 2022-01-11 CN CN202280020127.2A patent/CN117320716A/zh active Pending
- 2022-01-11 BR BR112023013828A patent/BR112023013828A2/pt unknown
- 2022-01-11 AU AU2022208237A patent/AU2022208237A1/en active Pending
- 2022-01-11 CA CA3208099A patent/CA3208099A1/en active Pending
- 2022-01-11 WO PCT/GB2022/050054 patent/WO2022153042A1/en not_active Ceased
- 2022-01-11 KR KR1020237027428A patent/KR20230159375A/ko active Pending
-
2023
- 2023-07-11 IL IL304392A patent/IL304392A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022208237A1 (en) | 2023-08-10 |
| CA3208099A1 (en) | 2022-07-21 |
| EP4277625A1 (en) | 2023-11-22 |
| KR20230159375A (ko) | 2023-11-21 |
| WO2022153042A1 (en) | 2022-07-21 |
| US20240082222A1 (en) | 2024-03-14 |
| CN117320716A (zh) | 2023-12-29 |
| AU2022208237A9 (en) | 2024-07-25 |
| JP2024505143A (ja) | 2024-02-05 |
| IL304392A (en) | 2023-09-01 |
| BR112023013828A2 (pt) | 2023-10-03 |
| GB202100352D0 (en) | 2021-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008263A (es) | 4-cloro-n[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benz amida para uso en medicina. | |
| Wang et al. | Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways | |
| MY140132A (en) | Thiazolidin-4-one derivatives for use in the treatment of anemias | |
| UA88257C2 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ С-α ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ПОЧЕК, КОТОРЫЕ ПРИВОДЯТ К ПРОТЕИНУРИИ, И ДИАБЕТИЧЕСКИМ РЕТИНОПАТИИ, НЕВРОПАТИИ ИЛИ НЕФРОПАТИИ | |
| BRPI0518011A (pt) | uso de tetraidrocanabidivarina, métodos para o tratamento de uma doença ou condição e para cosmeticamente beneficiar a perda de peso, e, uso de um antagonista do receptor de canabinóide neutro | |
| ATE328868T1 (de) | Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten | |
| BR0213540A (pt) | Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos | |
| EP4288048A4 (en) | OXA-IBOGAIN-INSPIRED ANALOGUES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | |
| DE602007008855D1 (de) | Verwendung von (s)-roscovitin zur vorbeugung und/oder behandlung von neurologischen erkrankungen | |
| BR112022008146A2 (pt) | Inibidores de adrenorreceptor adrac2 | |
| BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
| Kaufman et al. | Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| BR112023005987A2 (pt) | Composição farmacêutica, preparação farmacêutica, método de tratamento de uma doença ou disfunção associada à atividade de kdm1a em um paciente com sua necessidade, método de inibição de kdm1a e método para suprimir a proliferação de células mieloides malignas em um sujeito com sua necessidade | |
| DE69928521D1 (de) | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit | |
| CN104997575B (zh) | 一种适应不同类型股骨畸形和缺损的股骨假体组建系统 | |
| DE60118769D1 (de) | Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten | |
| DK1392676T3 (da) | Hidtil ukendte heterocykliske urinstofderivater og deres anvendelse som dopamin -D3 - receptorligander | |
| IL326583A (en) | Stable GLP-1 analogs for the treatment of human diseases and disorders | |
| Kulikov et al. | The first experience with brolucizumab for neovascular age-related macular degeneration | |
| ZA202311237B (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| CN104825450A (zh) | Dapk1抑制剂在制备抗抑郁药物中的应用 | |
| Hollins et al. | Advances in Soft Tissue Injuries Associated with Open Fractures | |
| Habenicht | AAO Case History# 4 |